A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis

Keitaro Yokoyama, Takashi Akiba, Masafumi Fukagawa, Masaaki Nakayama, Kenichi Sawada, Yuji Kumagai, Glenn M. Chertow, Hideki Hirakata

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background JTT-751 is a novel phosphate binder containing ferric citrate as the active ingredient. Methods In this Phase 3, multicenter, randomized, open-label, parallel-group study, we compared the efficacy and safety of JTT-751 and sevelamer hydrochloride in patients undergoing hemodialysis. A total of 230 patients with a serum phosphate 1.97 and <3.23 mmol/L were randomized to JTT-751 (dose adjusted between 1.5 and 6.0 g/day) or sevelamer hydrochloride (dose adjusted between 3.0 and 9.0 g/day) for 12 weeks. The primary outcome was change in serum phosphate from baseline to end of treatment. Secondary outcomes included the changes in corrected serum calcium and intact parathyroid hormone (PTH). The changes in ferritin, transferrin saturation and erythropoiesis- stimulating agent dose were additional outcomes. Results Changes in serum phosphate at the end of treatment were-0.82 mmol/L in the JTT-751 group and-0.78 mmol/L in the sevelamer group, establishing non-inferiority of JTT-751 compared with sevelamer (least squares mean,-0.03 mmol/L; 95% confidence interval,-0.13 to 0.07 mmol/L). Corrected serum calcium increased and PTH decreased from baseline within both groups; changes between groups were similar. Gastrointestinal disorders were the most common adverse events in both groups; the incidence of diarrhea was higher in the JTT-751 group, while constipation occurred frequently in the sevelamer group. Treatment with JTT-751 resulted in significant relative increases in serum ferritin and transferrin saturation. Conclusions Efficacy and safety of JTT-751 was comparable to sevelamer in patients on hemodialysis with hyperphosphatemia. Differential adverse effects were observed; biochemical markers of iron status increased in patients treated with JTT-751. Trial registration number CTI-111433 (The Japan Pharmaceutical Information Center at: http//www.clinicaltrials.jp). Date of registration: 7 March 2011.

Original languageEnglish
Pages (from-to)1053-1060
Number of pages8
JournalNephrology Dialysis Transplantation
Volume29
Issue number5
DOIs
Publication statusPublished - 2014 May

Keywords

  • Clinical trial
  • ferric citrate
  • hemodialysis
  • hyperphosphatemia
  • phosphate binder

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis'. Together they form a unique fingerprint.

  • Cite this

    Yokoyama, K., Akiba, T., Fukagawa, M., Nakayama, M., Sawada, K., Kumagai, Y., Chertow, G. M., & Hirakata, H. (2014). A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrology Dialysis Transplantation, 29(5), 1053-1060. https://doi.org/10.1093/ndt/gft483